CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Impact · against what's priced in

PTGX is positioned for significant value creation driven by 2026 regulatory decisions for rusfertide and ICOTYDE, combined with a strategic move to improve margins by opting out of a profit-sharing deal. Takeda faces a potential shift in the financial structure of its rusfertide partnership, which may reduce its share of the drug's US profits.

PTGX+0.70

No priced-in read yet